SYNH Stock Overview
Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Syneos Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$42.98 |
| 52 Week High | US$52.23 |
| 52 Week Low | US$22.89 |
| Beta | 1.58 |
| 1 Month Change | 0.66% |
| 3 Month Change | 1.99% |
| 1 Year Change | -8.84% |
| 3 Year Change | -23.06% |
| 5 Year Change | -10.61% |
| Change since IPO | 109.76% |
Recent News & Updates
Recent updates
Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?
Mar 29
Does Syneos Health (NASDAQ:SYNH) Have A Healthy Balance Sheet?
Mar 10Is Syneos Health, Inc. (NASDAQ:SYNH) Trading At A 40% Discount?
Feb 20Should You Investigate Syneos Health, Inc. (NASDAQ:SYNH) At US$34.33?
Dec 20Is Syneos Health (NASDAQ:SYNH) Using Too Much Debt?
Nov 28Here's Why Syneos Health (NASDAQ:SYNH) Has Caught The Eye Of Investors
Nov 01Syneos, Datavant expand partnership on data analytics for clinical trials
Oct 11Syneos Health falls 13% after update on outlook
Sep 13When Should You Buy Syneos Health, Inc. (NASDAQ:SYNH)?
Sep 08Is Syneos Health (NASDAQ:SYNH) A Risky Investment?
Aug 22Syneos Health Q2 2022 Earnings Preview
Aug 01With EPS Growth And More, Syneos Health (NASDAQ:SYNH) Makes An Interesting Case
Jul 19Syneos: Upside Could Be Priced In, Valuations Unsupportive
Jul 15Is There An Opportunity With Syneos Health, Inc.'s (NASDAQ:SYNH) 49% Undervaluation?
Jun 18Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?
Jun 03We Think Syneos Health (NASDAQ:SYNH) Can Stay On Top Of Its Debt
May 19Do Syneos Health's (NASDAQ:SYNH) Earnings Warrant Your Attention?
Apr 08Syneos Health: Upside Opportunity After Unexpected Correction In CRO Market, M&A Rumors
Mar 27Is Now An Opportune Moment To Examine Syneos Health, Inc. (NASDAQ:SYNH)?
Mar 05Is Syneos Health (NASDAQ:SYNH) A Risky Investment?
Feb 18Are Investors Undervaluing Syneos Health, Inc. (NASDAQ:SYNH) By 39%?
Feb 03With EPS Growth And More, Syneos Health (NASDAQ:SYNH) Is Interesting
Jan 04Syneos Health's Double-Digit Revenue Growth Sets The Tone For A Strong 2022
Dec 03Is It Too Late To Consider Buying Syneos Health, Inc. (NASDAQ:SYNH)?
Dec 03Shareholder Returns
| SYNH | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0.6% | -3.7% | -3.5% |
| 1Y | -8.8% | -6.6% | 22.1% |
Return vs Industry: SYNH exceeded the US Life Sciences industry which returned -13.4% over the past year.
Return vs Market: SYNH underperformed the US Market which returned 14.1% over the past year.
Price Volatility
| SYNH volatility | |
|---|---|
| SYNH Average Weekly Movement | 0.3% |
| Life Sciences Industry Average Movement | 9.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SYNH has not had significant price volatility in the past 3 months.
Volatility Over Time: SYNH's weekly volatility has decreased from 9% to 0% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 28,768 | Michelle Keefe | www.syneoshealth.com |
Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company. The company operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in Phase I to IV of clinical development.
Syneos Health, Inc. Fundamentals Summary
| SYNH fundamental statistics | |
|---|---|
| Market cap | US$4.46b |
| Earnings (TTM) | US$71.22m |
| Revenue (TTM) | US$5.42b |
62.6x
P/E Ratio0.8x
P/S RatioIs SYNH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYNH income statement (TTM) | |
|---|---|
| Revenue | US$5.42b |
| Cost of Revenue | US$4.22b |
| Gross Profit | US$1.20b |
| Other Expenses | US$1.13b |
| Earnings | US$71.22m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.69 |
| Gross Margin | 22.14% |
| Net Profit Margin | 1.31% |
| Debt/Equity Ratio | 75.8% |
How did SYNH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/09/29 07:59 |
| End of Day Share Price | 2023/09/27 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Syneos Health, Inc. is covered by 23 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Bolan | Avondale Partners |
| Eric Coldwell | Baird |
| Stewart Glickman | CFRA Equity Research |